FDG-PET reveals patterns in newly recognized fused in sarcoma proteinopathy

Wednesday, November 29 | 8:20 a.m.-8:30 a.m. | W1-SSNMMI05-3 | E350

FDG-PET may help differentiate patients with fused in sarcoma (FUS), a newly recognized proteinopathy causing progressive dementia, from those with Alzheimer’s disease (AD) and frontotemporal dementia (FTD), according to this presentation.

Proteinopathy is an umbrella term for distinct neurodegenerative disorders involving the accumulation of specific proteins in brain tissue.

In a postmortem study, researchers analyzed FDG-PET imaging data from 28 AD (70.1 ± 9.1 years old), 10 FTD (67 ± 6.7 years old), and three FUS (51.6 ± 17 years old) patients compared to 51 age-similar normal subjects. Autopsies assessed the presence of amyloid, tau, alpha-synuclein, ubiquitin, and fused in sarcoma protein with immunohistochemistry.

Ultimately, the FUS subjects, who were much younger on average, showed patterns of decreased FDG uptake similar to those of FTD, with prominent reductions in the anterior temporal lobe, orbitofrontal cortex, and caudate head (-33% as compared with -22% in FTD). Additionally, FDG uptake in anterior cingulate cortex was equally reduced in FTD and FUS (-20% and -22%), according to the findings.

“In the absence of protein-specific radiotracers to stratify neurodegenerative dementias, FDG has value to aid in a differential diagnosis, when the characteristic hypometabolic patterns are identified,” noted Donna Cross, PhD, of the University of Utah in Salt Lake City, who will present the study.

Attend this Wednesday morning scientific session on neuroradiology molecular imaging to learn all the details.